RELAX-AHF-II (Completed)
A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients
- Medicine
- RLX030 serelaxine
- Population
- Heart failure
- Phase
- III
- Starting year
- 2013
- More information
- ClinicalTrials.gov